Quantcast
Last updated on April 19, 2014 at 13:20 EDT

Latest Methotrexate Stories

2010-06-28 09:17:00

Study shows ITMTX may have beneficial role in progressive forms of MS NEW YORK, June 28 /PRNewswire-USNewswire/ -- The Multiple Sclerosis Research Center of New York (MSRCNY), together with the International Multiple Sclerosis Management Practice (IMSMP), today announced that results from its Intrathecal Methotrexate Treatment in Multiple Sclerosis study have been published in this month's issue of Journal of Neurology. This study reports on the feasibility of using intrathecal...

2010-06-16 08:30:00

ATLANTA, June 16 /PRNewswire-FirstCall/ -- UCB today announced new Cimzia® (certolizumab pegol) data demonstrating rapid and sustained improvements in managing moderate to severe rheumatoid arthritis (RA) symptoms and pain for patients, as well as results of a survey showing the impact of RA pain on the daily lives of women, focusing on productivity and relationships, during the 2010 European League Against Rheumatism (EULAR) annual congress in Rome, Italy, June 16-19....

2010-01-14 14:35:22

Clinical trials to test the effectiveness of two prescription drugs for the debilitating skin condition psoriasis have revealed significant differences that should help inform physicians treating patients with the condition. Researchers at The University of Manchester compared the drugs etanercept and ustekinumab "“ relatively new biological therapies that have proved effective in the management of moderate to severe psoriasis. Little research has been done to test the benefit-risk...

2009-12-16 07:30:00

MOUNTAIN VIEW, Calif., Dec. 16 /PRNewswire/ -- ChemoCentryx, Inc. today announced that it has begun enrolling patients in a Phase 2 clinical trial of CCX354, an orally-bioavailable, novel, small molecule drug designed to specifically target the CCR1 chemokine receptor for the treatment of rheumatoid arthritis (RA). CCX354 is a highly potent and selective antagonist of CCR1, a chemokine receptor that drives the recruitment of immune cells, such as monocytes and macrophages, associated...

2009-12-01 12:10:40

Chicken collagen can provide relief from rheumatoid arthritis (RA) symptoms. A randomized, controlled trial, published in BioMed Central's open access journal Arthritis Research & Therapy, has found that Chicken type II collagen (CCII), a protein extracted from the cartilage of chicken breast, is a safe and effective treatment for RA. Wei Wei, from Anhui Medical University, China, worked with a team of researchers to test the novel treatment by comparing it to the established...

2009-10-19 07:05:00

PHILADELPHIA, Oct. 19 /PRNewswire/ -- New long-term data from two pivotal, Phase 3 clinical trials showed that patients with active rheumatoid arthritis (RA) receiving SIMPONI(TM) (golimumab) every four weeks achieved sustained improvements in signs and symptoms and physical function response through one year. These new data were presented today at the 2009 American College of Rheumatology (ACR) Annual Scientific Meeting. "New data demonstrate sustained efficacy of golimumab dosed...

2009-10-19 07:02:00

PHILADELPHIA, Oct. 19 /PRNewswire/ -- Phase 3 data reported for the first time show that once every four week subcutaneous injections of SIMPONI(TM) (golimumab) resulted in significantly greater inhibition of structural damage compared with placebo plus methotrexate in patients with active rheumatoid arthritis (RA) and active psoriatic arthritis (PsA). Radiographic analyses showed that treatment with SIMPONI resulted in a statistically significant reduction in change from baseline in...

2009-10-14 11:59:42

Medications that block folic acid are associated with increased abnormalities Using medication that reduces or blocks the actions of folic acid during the first trimester of pregnancy (weeks 1-12), increases the risk that the growing baby will develop abnormalities. This conclusion was reached by a team of Epidemiologists, Paediatricians, Clinical Pharmacologists, Obstetricians and Gynecologists who examined birth and abortion data collected in Israel between 1998 and 2007. The study drew...

2009-09-28 13:34:00

MENLO PARK, Calif. and NEW YORK and BIRMINGHAM, Ala., Sept. 28 /PRNewswire/ -- The U.S. Food & Drug Administration has announced the approval of pralatrexate for the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL). Research on drugs of this class began in the 1950s at SRI International. A subsequent scientific collaboration among SRI International, Memorial Sloan-Kettering Cancer Center, and Southern Research Institute led to clinical trials on related compounds...

2009-09-25 17:24:00

MENLO PARK, Calif., NEW YORK and BIRMINGHAM, Ala., Sept. 25 /PRNewswire/ -- The U.S. Food & Drug Administration has announced the approval of pralatrexate for the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL). Research on drugs of this class began in the 1950s at SRI International. A subsequent scientific collaboration among SRI International, Memorial Sloan-Kettering Cancer Center, and Southern Research Institute led to clinical trials on related compounds...